Phase 3 of Danicopan will be conducted in Korea
By Lee, Hye-Kyung | translator Choi HeeYoung
22.06.28 06:18:09
°¡³ª´Ù¶ó
0
Long-term extension test in 7 university hospitals for patients with seizure and PNH
The MFDS recently approved a phase 3 clinical trial for patients with seizure night hemoglobinuria (PNH) who had previously been administered Danicopan in a clinical trial commissioned by IQVIA.
This clinical trial is an additional therapy for C5i and is a long-term extension (LTE) test to characterize Danicopan's safety and effectiveness. It is conducted at Seoul St. Mary's Hospital, Sung Vincent Hospital, Severance Hospital, Chungnam National University Hospital, Seoul Asan Hospital, and Samsung Medical Center.
Danicopan is a PO Factor D i
Lee, Hye-Kyung(hgrace7@dailypharm.com)
If you want to see the full article, please JOIN US (click)